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Currently, little is known about the ankyrin/F-box protein B4. Here, we report that B4R-null viruses
exhibited reduced plaque size in tissue culture, and decreased ability to spread, as assessed by multiple-
step growth analysis. Electron microscopy indicated that B4R-null viruses still formed mature and
extracellular virions; however, there was a slight decrease of virions released into the media following
deletion of B4R. Deletion of B4R did not affect the ability of the virus to rearrange actin; however,
VACV811, a large vaccinia virus deletion mutant missing 55 open reading frames, had decreased ability to
produce actin tails. Using ectromelia virus, a natural mouse pathogen, we demonstrated that virus
devoid of EVM154, the B4R homolog, showed decreased spread to organs and was attenuated during
infection. This initial characterization suggests that B4 may play a role in virus spread, and that other
unidentiﬁed mediators of actin tail formation may exist in vaccinia virus.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The Poxviridae comprise a unique family of viruses distinguished
by a single linear double-stranded DNA (dsDNA) genome, a large
brick-shaped virion, and the ability to replicate exclusively in the
cytoplasm of an infected cell (Moss, 2007). The most well-known
member of the Poxviridae family, variola virus, is the causative agent
of smallpox, a disease that killed more humans in recorded history
than all other infectious diseases combined (Fenner et al., 1988).
Although smallpox was eradicated in 1977 through a dedicated
effort by the World Health Organization (Fenner et al., 1988), other
poxviruses cause clinically relevant diseases in animals and
humans, and recent outbreaks of monkeypox virus underline the
importance of studying these viruses (Reed et al., 2004). The use of
poxviruses for gene-delivery vectors and oncolytic therapies has
also generated interest in studying poxvirus biology (Seet et al.,
2003; Thorne, 2011).
Poxviruses form two types of infectious particles, mature
virions (MV; also known as intracellular mature virus, IMV), and
extracellular virions (EV; also known as extracellular enveloped
virus, EEV) (Condit et al., 2006; Moss, 2007). Virion production has
been well studied in vaccinia virus (VACV). The process begins in
the virus factories with the formation of crescent-shaped struc-
tures, comprised of lipids and virion core proteins, which surround
the newly replicated DNA genome (Dales and Mosbach, 1968;
Moss, 2007). Poxviruses encode a scaffold protein that provides a
stable structure in order for the lipid bilayer to form (Heuser,
2005; Szajner et al., 2005), and proteins synthesized in the
endoplasmic reticulum are transported to the growing lipid bilayer
(Husain et al., 2006, 2007b). An immature virion (IV) is formed
once the lipid bilayer fully encloses the core (Condit et al., 2006;
Moss, 2007). Transition to infectious MV occurs following genome
packaging, proteolytic cleavage, loss of the D13 scaffold protein,
association of additional membrane proteins, and core rearrange-
ment (Condit et al., 2006). While most virus is thought to be
released upon cell lysis, some MVs can undergo additional
maturation steps, which are thought to aid in their exit prior to
lysis. In this process, MVs are transported away from virus
factories and acquire two additional lipid membranes from either
endosomes or the trans-Golgi network to become wrapped virions
(WV) (see Table 1 for a list of genes involved in this process). WVs
are then transported along microtubules to the cell surface, where
they fuse with the plasma membrane and lose one set of
membranes to become EVs (Geada et al., 2001; Hollinshead
et al., 2001; Rietdorf et al., 2001; Ward and Moss, 2001a). EVs
can be immediately released, or remain associated with the
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outside of the plasma membrane and catalyze the formation of
actin tails to infect adjacent cells (Blasco and Moss, 1992; Cudmore
et al., 1995). MVs mediate host-to-host transmission, while EVs,
the less abundant of the two, mediate spread within an infected
host (Smith et al., 2003). Generally, disruption of the genes
involved in virion formation and transport confers a small-
plaque phenotype in cell culture, and results in reduced virulence
in vivo; this has been extensively reviewed (Roberts and Smith,
2008a; Smith and Law, 2004)
Within the B HindIII region of the VACV genome, a number of
open reading frames (ORFs) have been characterized; however, the
role of B4R during poxvirus infection remains unknown. B4 contains
multiple Ankyrin (Ank) domains in conjunction with a C-terminal
F-box (Mercer et al., 2005; Sonnberg et al., 2008); a combination that
was unique to poxviruses until recently, when Ank/F-box proteins
were identiﬁed in the parasitoid wasp, Nasonia (Werren et al., 2010).
The F-box domain is necessary for interaction with Skp1 in the SCF
ubiquitin ligase, an important mediator of protein degradation (Bai et
al., 1996; Nakayama and Nakayama, 2006). Cellular F-box proteins
recruit substrates to the SCF to be ubiquitinated (Kipreos and Pagano,
2000). Ank repeats are present in a number of cellular proteins, and
mediate distinctive protein–protein interactions (Li et al., 2006).
Ank repeats have been implicated in a number signaling events
that regulate cell cycle control, cell differentiation, apoptosis, and
vesicular trafﬁcking (Li et al., 2006).
Here, we sought characterize the role of B4 during poxvirus
infection. We report that deletion of B4R resulted in a reduction in
plaque size. We demonstrate that viruses lacking B4R progressed
through the stages of crescent, IV, MV, WV, and EV formation, but
show decreased levels of virions released in the media. Further-
more, using an ectromelia (ECTV) mouse model, we demonstrate
that deletion of the homolog of B4R, EVM154, resulted in reduced
spread of the virus to the spleen, liver, lungs, and kidneys, and
attenuation of the virus. This initial characterization suggests that
B4 might contribute to virion spread.
In addition, we used the large deletion virus, vaccinia virus strain
811 (VACV811) to further probe the question of virus spread. This
virus was strategically engineered by progressive deletions and lacks
a total of 55 ORFs, when compared to the parental VACV Copenha-
gen. This includes 38 ORFs from the left end of the genome (C23L to
F4L) and 17 from the right end (B13R to B29R) (Perkus et al., 1991;
Fagan-Garcia and Barry, 2011). Despite the large number of genes
missing from this virus, VACV811 encodes all genes known to
contribute to efﬁcient virus formation and spread (Table 1). Here,
Table 1
Summary of VACV genes important for virus spread and infectivity.
Gene class Gene Activity References
Virion release
and spread
A27L Transport MV away from virus factory; also implicated in
wrapping
(Blasco et al., 1991; Howard et al., 2010; Ward, 2005)
A33R Important for wrapping; anchors A36 to viral
membrane, thus aiding actin projectile formation
(Breiman et al., 2013; Chan et al., 2010; Chan and Ward, 2010, 2012a, b; Katz et al.,
2003; Roper et al., 1996; Roper et al., 1998; Ward et al., 2003; Wolffe et al., 2001)
A34R Regulate WV formation and rate of EV release; may be
involved in actin projectile formation
(Blasco et al., 1993; Breiman et al., 2013; Breiman and Smith, 2010; Earley et al., 2008;
Husain et al., 2007a; McIntosh and Smith, 1996; Perdiguero et al., 2008;
Vanderplasschen et al., 1998; Wolffe et al., 1997)
A36R Anchors F12 to WV for transport to cell surface along
microtubules; essential for actin projectile formation
(Frischknecht et al., 1999; Herrero-Martinez et al., 2005; Horsington et al., 2013;
Humphries et al., 2012; Johnston and Ward, 2009; Newsome et al., 2006; Rietdorf
et al., 2001; Rottger et al., 1999; Sanderson et al., 1998; van Eijl et al., 2000; Ward and
Moss, 2004; Wolffe et al. 1998, 2001)
B5R Important for wrapping; stimulates actin projectile
formation
(Chan and Ward, 2010; Earley et al., 2008; Engelstad et al., 1992; Engelstad and Smith,
1993; Herrera et al., 1998; Isaacs et al., 1992; Katz et al., 2003; Katz et al., 2002; Katz
et al., 1997; Mathew et al., 1998; Mathew et al., 1999; Mathew et al., 2001; Newsome
et al., 2004; Rottger et al., 1999; Ward and Moss, 2001b; Wolffe et al., 1993)
E2L Transport WV to cell surface; also implicated in
wrapping
(Dodding et al., 2009; Domi et al., 2008; Morgan et al., 2010; Rottger et al., 1999)
F11L Transport WV to cell surface; important for disruption of
actin and transition from WV to EV
(Arakawa et al., 2007a; Arakawa et al., 2007b; Cordeiro et al., 2009; Handa et al., 2013;
Morgan et al., 2010)
F12L Transport WV to cell surface (Dodding et al., 2009; Morgan et al., 2010; van Eijl et al., 2002; Zhang et al., 2000)
F13L Important for wrapping; has phospholipase activity (Blasco and Moss, 1991; Borrego et al., 1999; Honeychurch et al., 2007; Husain and
Moss, 2001, 2002, 2003; Husain et al., 2003; Roper and Moss, 1999; Schmelz et al.,
1994)
Binding to
cell surface
A25L/
A26L
Mediates binding/fusion; probably determines
preference for endocytic or direct fusion pathway
(Chiu et al., 2007)
A27L Mediates binding to heparan sulfate (Chung et al., 1998; Hsiao et al., 1998)
D8L Mediates binding to chondroitin sulfate (Hsiao et al., 1999)
H3L Mediates binding to heparan sulfate (Lin et al., 2000)
Entry-fusion
complex
(EFC)
A16L Transmembrane protein; mediates internalization (Ojeda et al., 2006b)
A21L Transmembrane protein; mediates internalization (Townsley et al., 2005b)
A28L Transmembrane protein; mediates internalization Senkevich et al. (2004a, b)
G3L Transmembrane protein; mediates internalization (Izmailyan et al., 2006; Senkevich et al., 2005; Turner et al., 2007)
G9R Transmembrane protein; mediates internalization (Ojeda et al., 2006a)
H2R Transmembrane protein; mediates internalization (Nelson et al., 2008; Senkevich and Moss, 2005)
J5L Transmembrane protein; mediates internalization (Wolfe et al., 2012)
L5R Transmembrane protein; mediates internalization (Townsley et al., 2005a)
O3L Membrane-associated; mediates fusion (Satheshkumar and Moss, 2009, 2012)
Associated
with EFC
F9L Membrane-associated; mediates fusion (Brown et al., 2006)
L1R Membrane-associated; mediates fusion (Bisht et al., 2008)
May be
associated
with EFC
I2L Membrane-associated; mediates fusion (Nichols et al., 2008)
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we demonstrate that VACV811 had decreased ability to produce actin
tail formation. Furthermore, we demonstrate that deletion of B4R
from VACV811 produced a decrease in virus spread compared to
deletion from VACV, suggesting that B4 might work in cooperation
with another protein missing from VACV811.
Results
Deletion of B4R seems to reduce the ability of VACV to spread
in tissue culture
The purpose of this study was to perform initial characteriza-
tion studies on the Ank/F-box protein B4. Using homologous
recombination, we generated a deletion virus from VACV strain
Copenhagen, VACVΔB4R, which contains a YFP/gpt cassette in place
of the B4R ORF (Rintoul et al., 2011). A revertant virus, VACVΔB4R-rev,
was also generated. To determine if the B4 protein was important for
virus propagation in tissue culture, a plaque assay was performed
(Fig. 1). VACV, VACVΔB4R, or VACVΔB4R-rev, were serially diluted
and titered on BGMK cells and plaques were allowed to form for a
period of up to ﬁve days. At two days post infection, VACV and
VACVΔB4R-rev produced large, round plaques, and secondary plaque
formation was visible three days post-infection (Fig. 1A a–c and g–i).
At ﬁve days post-infection, all of the cells infected with VACV and
VACVΔB4R-rev were lysed, and plaques were no longer visible
(Fig. 1A). Interestingly, plaques formed by VACVΔB4R were smaller
when compared to VACV or VACVΔB4R-rev, indicating that the B4
Fig. 1. Effect of deleting B4R on plaque size in tissue culture: (A) plaque sizes. BGMK cells were infected with VACV (a–c), VACVΔB4R (d–f), VACVΔB4R-rev (g–i), VACV811
(j–l), VACV811ΔB4R (m–o), or VACV811ΔB4R-rev (p–r). Cells were stainedwith crystal violet 2 days (a, d, g, j, m, p), 3 days (b, e, h, k, n, q), or 5 days post-infection (c, f, i, l, o, r). (B, C,
and D) Comparison of plaque sizes. 45 plaques were measured over three independent experiments using ImageJ. GraphPad was used to determine signiﬁcant differences in plaque
size between viruses. n.s., not signiﬁcant; n.d., no data.
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protein might contribute to virus spread in tissue culture (Fig. 1A d–f).
Since the large deletion virus VACV811 also had a reduction in plaque
size compared to VACV (Fig. 1A j–o), we generated the deletion virus
VACV811ΔB4R, also containing a YFP/gpt cassette in place of the B4R,
to determine if the reduction in plaque size was affected by further
loss of B4R (Fig. 1A m–o). The revertant virus, VACV811ΔB4R-rev, was
also generated (Fig. 1A p–r). Strikingly, plaque formation by VACV811
was signiﬁcantly reduced compared to VACV (Fig. 1A j and k). Plaques
formed by VACV811ΔB4R were barely visible following ﬁve days of
infection, indicating that deletion of B4R again resulted in a reduction
in plaque size (Fig. 1A m–o). VACV811ΔB4R-rev and VACV811 formed
the same sized plaques, indicating that the method of deletion did
not affect the virus elsewhere in the genome (Fig. 1A j and p).
Statistical analysis further conﬁrmed our results (Fig. 1B–D).
To determine the replicative capacity of viruses devoid of the
B4 protein, we used single-step growth analysis (Fig. 2A). BGMK
cells were infected at a MOI of 10 with VACV, VACVΔB4R,
VACVΔB4R-rev, VACV811, VACV811ΔB4R, or VACV811ΔB4R-rev.
One hour post-infection, inoculum was removed and incubated
with fresh medium. At 0, 4, 8, 12, 24 and 48 h post-infection,
media and cells were harvested and virus was released by three
freeze-thaw cycles followed by sonication. Similar levels of virus
replication occurred, suggesting no defect in viral replication
(Fig. 2A). Typically, a reduction in plaque size is indicative of
decreased virion morphogenesis, release, or spread. For instance,
deletion of the VACV genes A33R, A34R, A36R, B5R, F12L, or F13L
results in a small plaque phenotype (Blasco and Moss, 1991; Domi
et al., 2008; Duncan and Smith, 1992; Parkinson and Smith, 1994;
Roper et al., 1996; Wolffe et al., 1993; Zhang et al., 2000) (Table 1).
We used a multi-step growth curve to examine EV formation and
virus spread (Fig. 2B). BGMK cells were infected with the indicated
viruses and samples were harvested at 0, 12, 24, 48, and 72 h post-
infection. The titers of VACVΔB4R and VACVΔB4R-rev were not
signiﬁcantly lower compared to VACV. However, in all three
experimental replicates, VACV811 grew to titers two logs lower
than VACV, while the titers of VACV811ΔB4R were approximately
half to one full log less than VACV811 (Fig. 2B). The revertant
VACV811ΔB4R-rev grew as well as its parental virus, again
indicating that the method of deletion did not affect the virus
elsewhere in the genome. Together, these data conﬁrmed that
VACV811 is defective in spread compared to VACV, and suggested
that the loss of B4R from VACV811 decreases the ability of
VACV811 to spread in tissue culture.
Late genes are still synthesized in viruses devoid of B4R
Since late gene synthesis is required for virion production
(Moss, 2007), we wanted to determine if loss of B4 altered late
gene synthesis. For this, BGMK cells were infected with VACV,
VACVΔB4R, VACV811, or VACV811ΔB4R and whole cell lysates
were collected at the indicated times post-infection. Samples were
immunoblotted for E3, a VACV protein that is expressed early
during infection, and B5, A34, and I5, which are expressed late
during infection (Assarsson et al., 2008; Broyles, 2003) (Fig. 3).
In cells infected with VACV and VACV811, expression of E3
occurred almost immediately and protein levels increased during
Fig. 2. Analysis of virus growth following deletion of B4R. BGMK cells were
infected with VACV, VACVΔB4R, VACVΔB4R-rev, VACV811, VACV811ΔB4R, or
VACV811ΔB4R-rev at a MOI of 10 for single-step growth analysis (A) and at a
MOI of 0.01 for multiple-step growth analysis (B). Infected cells were harvested and
lysed to release infectious virus. Serial dilutions of infectious virus were plated on
BGMK cells. Infected monolayers were ﬁxed and stained with crystal violet and
plaques were counted to generate growth curves. Representative of three inde-
pendent experiments, each titered in duplicate.
Fig. 3. Effect on late gene synthesis in viruses devoid of B4R. BGMK cells were infected with VACV, VACVΔB4R, VACV811, or VACV811ΔB4R at a MOI of 10. Whole cell lysates
were harvested at the indicated times post infection and immunoblotted for the early protein E3, and the late proteins B5, A34, and I5. β-tubulin was used as a loading
control.
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the course of infection (Fig. 3). Expression of the late proteins
B5, A34, and I5 began at six hours post-infection and continued to
increase throughout infection (Fig. 3). In all cases, the mutant
viruses expressed the indicated proteins to levels similar to their
respective parental strain, suggesting that deletion of B4R does not
affect late protein expression (Fig. 3).
Viruses devoid of B4R form virus particles, but exhibit decreased
EV release into the media
Since late genes were being produced in viruses devoid of B4R,
we sought to determine whether EV formation was prevented at
some step, using transmission electron microscopy (Fig. 4). BGMK
cells were infected at a MOI of 10 with VACV (Fig. 4a–g),
VACVΔB4R (Fig. 4h–n), VACV811 (Fig. 4o–u), or VACV811ΔB4R
(Fig. 4v–bb). Fixed cells were visualized by transmission electron
microscopy to observe the stages of virion assembly (Duncan and
Smith, 1992). In cells infected with VACV and VACVΔB4R, cres-
cents (Fig. 4b and i), immature virions (Fig. 4d and k), MVs (Fig. 4e
and l), WVs (Fig. 4f and m), and EVs (Fig. 4g and n) were
visualized; indicating that loss of the B4 protein did not prevent
EV production. In addition, cells infected with VACV811 (Fig. 4o–u)
or VACV811ΔB4R (Fig. 4v–bb) displayed similar results, indicating
that virion formation is not hindered. To determine if the same
numbers of virions are released from cells infected with the
various viruses, we performed a media release assay (Fig. 5).
BGMK cells were infected at a MOI of 10 with VACV, VACVΔB4R,
VACV811, or VACV811ΔB4R. Supernatant and cellular fractions
were harvested 24 h post-infection, and samples were titered to
determine the percentage of virions in the media compared to the
total number of virions. Interestingly, we observed a lower number
of virions being released from cells infected with VACV811ΔB4R
compared to VACV811 (Fig. 5). There was no signiﬁcant difference
in the number of virions released from cells infected with
VACVΔB4R compared to VACV (Fig. 5). It is possible that the
effect is more pronounced since more genes are missing from
VACV811, and one or more gene products may work cooperatively
with B4.
Fig. 4. Transmission electron microscopy of infected cells. BGMK cells were infected at a MOI of 10 with VACV (a–g), VACVΔB4R (h–n), VACV811 (o–u), or VACV811ΔB4R
(v–bb). Twenty-four hours post-infection, cells were ﬁxed, sectioned, and visualized using transmission electron microscopy. Micrographs display crescent formation (b, c, i,
j, p, l, w, x), IV (d, k, r, y), MV (e, l, s, z), WV (f, m, t, aa), and CEV (g, n, u, bb). Arrows indicate membranes.
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Deletion of B4R does not affect actin tails
Following fusion of WV with the cell membrane, the virion
remains associated with the membrane until it initiates a rearran-
gement of actin that projects it away from the cell (Roberts and
Smith, 2008b; Smith et al., 2002; Welch and Way, 2013). Since
VACV811 devoid of B4R had reduced numbers of virions released
from the cell, we sought to determine if formation of actin tails
was impaired by loss of B4R (Fig. 6). BSC-1 cells on coverslips were
infected at a MOI of 10 with VACV, VACVΔB4R, VACV811, or
VACV811ΔB4R. Twenty hours post-infection, cells were stained
with phalloidin to visualize actin tails, and to the viral EV protein
B5, to observe the location of WVs and EVs in the cell (Fig. 6A).
Mean number of projectiles per cell was quantiﬁed by counting
the actin tails in 50 cells in each of three separate trials (Fig. 6B).
Cells infected with viruses devoid of B4R formed actin tails as well
as their respective parental strain; however, we noticed a decrease
in the number of actin tails formed in cells infected with VACV811
compared to cells infected with VACV (Fig. 6B). Notably, we
observed that the localization of B5, a WV/EV speciﬁc protein,
was not drastically altered by the presence of B4 (Fig. 6A).
The ECTV-mouse model indicates that loss of B4R results in virus
attenuation
Since our data suggested that B4 might be important for the
virus infection cycle, we wanted to determine whether B4 con-
tributed to virus virulence in vivo. Mouse models are useful for
studying poxvirus infection; however, VACV is not a natural
pathogen to mice. Infection with ECTV, the natural pathogen of
mice, is a well-established model to study poxvirus–host interac-
tions (Esteban et al., 2012; Esteban and Buller, 2005). ECTV
contains a homolog to B4R, EVM154. The amino acid sequences
of EVM154 and B4R are 94% identical, and both ORFs contain the
same domains: an F-box domain at the C-terminus which has
been demonstrated to be functional, and six Ank domains dis-
persed throughout the N-terminus (van Buuren et al., 2008). To
study the contribution of B4R in vivo, we generated an ECTV
devoid of EVM154. A revertant was also generated. To assess the
role of EVM154 in spread, we performed a plaque assay similar to
the one described above (Fig. 2), where ECTV, ECTVΔ154, or
ECTVΔ154-rev were serially diluted and titered on BGMK cells
and plaque formation was analyzed after 3, 4, and 5 days post-
infection (Fig. 7). In agreement with our observations in VACV,
ECTV devoid of EVM154 formed smaller plaques than its parental
virus, ECTV, or the revertant virus, ECTVΔ154-rev (Fig. 7).
Since deletion of EVM154 demonstrated similar results to
deletion of B4R, we turned to our mouse model to determine if
B4R/EVM154 played a role in virus virulence (Fig. 8A–D). C57BL/6
mice were infected intranasally with ECTV or ECTVΔ154. Mice
were sacriﬁced at the indicated days post-infection, and tissue
from the liver, spleen, lungs, and kidneys was harvested. The
amount of virus present was determined by titration. While wild
type ECTV exhibited high titers in all organs after seven days of
infection, an increase in ECTVΔ154 viral titers was not detected in
Fig. 5. Effect on virion release following deletion of B4R. BGMK cells were infected
at a MOI of 10 with VACV, VACVΔB4R, VACV811, or VACV811ΔB4R. Twenty-four
hours post-infection, media were harvested and cellular debris was removed by
centrifugation. Cell monolayers were harvested in PBS and freeze-thawed three
times to release virus particles. The media and cell fractions were titered and the
values were used to determine the number of virions that were released from the
cell. The amount of released virus, as a percent of total virus (releasedþcell-
associated) was then calculated. The experiment was performed in triplicate, and
standard error of the mean (SEM) was determined. n.s., not signiﬁcant.
Fig. 6. Effect on actin tail formation following deletion of B4R: (A) BGMK cells were
infected at a MOI of 10 with VACV, VACVΔB4R, VACV811, or VACV811ΔB4R. Twenty
hours post-infection, cells were stained for B5 to visualize virion distribution, actin
to visualize tails, and DAPI to visualize the nucleus. (B) Quantiﬁcation of actin tails.
Data were quantiﬁed by counting 150 cells over three separate experiments. n.s.,
not signiﬁcant.
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any of the organs, indicating a signiﬁcant defect in the ability of
ECTVΔ154 to spread within the mouse. Survival of the mice was
also monitored at the indicated days post-infection (Fig. 8E). Mice
infected ECTV succumbed to infection 8 days post-infection. In
contrast, mice infected with ECTVΔ154 survived infection, further
conﬁrming that EVM154 was important for virulence.
Discussion
The purpose of this study was to perform initial characteriza-
tion of B4. We found that deletion of B4R from VACV resulted in a
reduction in plaque size in tissue culture (Fig. 1), and a slight
decrease in virion spread, as assessed using a multi-step growth
curve (Fig. 2B). Deletion of the homolog of B4R, EVM154, from
ECTV also results in a reduction in plaque size (Fig. 7), lending
further support to the idea that this gene may play a role in
Orthopoxvirus spread.
For our experiments, we also utilized the large deletion virus
VACV811, which lacks 55 ORFs, to further investigate the role of B4
in spread. Interestingly, VACV811 contains all of the currently
known ORFs that are implicated in release and spread (Table 1),
yet compared to VACV, VACV811 produced plaques that were
reduced in size (Fig. 1) and showed decreased growth in a
multiple-step growth curve (Fig. 2B). Following deletion of B4R,
we observed that VACV811ΔB4R produces smaller plaques than
VACV811 (Fig. 1), and multiple-step growth analysis suggested that
VACV811ΔB4R is defective in release or spread (Fig. 2B).
While the exact mechanism as to how B4 contributes virus
spread remains elusive, we ruled out the possibility that B4 might
be important for MV morphogenesis since these deletion viruses
underwent all stages of viral morphogenesis (Fig. 4) and grew to
similar levels under high MOI, single-step growth analysis
(Fig. 2A). Furthermore these viruses appeared to support similar
levels of late gene synthesis (Fig. 3). The disruption of the B4R
gene did not affect the production, or localization, of the adjacent
B5R gene (a gene known to be important for EV/actin tail
formation) suggesting that these observations were not the result
of an unintended disruption of B5R (Figs. 3 and 6).
We did observe that cells infected with VACV811ΔB4R released
fewer viruses into the medium of infected cells than the parental
VACV811 strain (Fig. 5). Bioinformatics predicts that B4 encodes
six Ank repeats, and these domains have been shown to be
involved in a number of processes, such as maintenance of the
actin cytoskeleton, cytoskeleton rearrangement, and linking mem-
brane proteins to the cytoskeletons (Cunha and Mohler, 2009).
Given that the rearrangement of actin plays an important role
in viral release and spread (Arakawa et al., 2007a, 2007b;
Frischknecht et al., 1999; Hiller et al., 1979; Horsington et al.,
2013; Reeves et al., 2005) we examined whether B4 affected the
formation of actin tails. The presence of B4R did not seem to affect
the frequency of actin tails formed by VACV-infected cells; how-
ever, VACV811 formed signiﬁcantly fewer actin tails than VACV
(Fig. 6). Since VACV811 is thought to encode all known genes in
EV/actin tail formation it suggests that there may be additional,
yet-to-be identiﬁed, viral genes involved in these processes that
are absent in VACV811.
Another question that remains is why there was a signiﬁcant
reduction in plaque size following deletion of B4R from VACV
(Fig. 1), yet there was no signiﬁcant difference in the number of
virions released from cells infected with each virus (Fig. 5). One
possibility is that B4 plays a role in cell motility during infection. It
has been established that actin dynamics affect cell motility;
however, there was no reduction in actin tails in cells infected
with VACVΔB4R compared to VACV (Fig. 6). Interestingly, reintro-
duction of F11L, an important mediator of actin formation, into
Fig. 7. Effect of deleting EVM154 on plaque size in tissue culture: (A) plaque sizes.
BGMK cells were infected with ECTV (a–c), ECTVΔ154 (d–f), or ECTVΔ154-rev (g–i). Cells
were stained with crystal violet 3 days (a, d, g), 4 days (b, e, h), or 5 days (c, f, i, l, o, r)
post-infection. (B, C, and D) Comparison of mean plaque sizes. 45 photographed plaques
were measured over three experiments using ImageJ and analyzed using GraphPad to
determine signiﬁcant differences in plaque size between viruses. n.s., not signiﬁcant.
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myxoma or modiﬁed vaccinia Ankara (MVA), did not restore cell
motility to the same degree as motility seen in wild-type VACV,
suggesting that an additional gene maybe involved in VACV-
mediated cell motility (Irwin and Evans, 2012; Valderrama et al.,
2006; Zwilling et al., 2010). Whether B4 plays a role in this
phenomenon will be explored in the future.
Many poxviral proteins that are important for release and
spread are packaged into the virion; however, B4 has not been
identiﬁed in the VACV virion (Moss, 2007). No work has been done
to characterize the ECTV virion, so whether EVM154 is packaged is
unknown; however, given the similarities in genes encoded by
VACV and ECTV, one would predict EVM154 is also absent from
virions. Moreover, transfection experiments have indicated that
B4R/EVM154 are expressed diffuse throughout the cytoplasm
(data not shown), further suggesting that this protein is not
incorporated into the virion.
B4R/EVM154 contain Ank/F-box domains that are important for
modulating the SCF ubiquitin ligase. Some poxviral proteins that
mediate release and spread require post-translational modiﬁcations
in order to function. For instance, F13 is palmitoylated, and A34 is
glycosylated (Breiman and Smith, 2010; Grosenbach et al., 1997). It is
possible that some poxviral proteins that are important for virion
release and spread might require processing by the proteasome, an
event that could be mediated by B4R/EVM154. Promoter analysis and
semi-quantitative RT-PCR indicate that B4R/EVM154 is a late gene
(data not shown), so this speculation is not unreasonable. Unfortu-
nately, with the exception of the GRR signal that mediates processing
of the NFκB precursors p100 and p105, proteasomal processing
motifs are not well characterized (Lin and Ghosh, 1996). Conse-
quently, it is difﬁcult at this point to screen the poxviral proteins to
determine if any of them contain proteasomal-processing signals.
Our results with VACV811 present a number of interesting
observations and indicate that there may be additional unidenti-
ﬁed ORFs that contribute to virion release, spread, or infectivity.
Importantly, our data also suggest a possible role for B4, a protein
that has until now remained uncharacterized. The importance of
B4 was underlined when we infected mice with ECTV devoid of
EVM154, the homolog of B4R, and saw decreased virus spread to
the liver, lung, kidneys, and spleen (Fig. 8). Additionally, survival
curves indicated that a virus devoid of EVM154 was attenuated. An
important consideration is the MOI that was used during our
experiments. Though a reduction in plaque size and restriction in a
Fig. 8. (A–D) Organ titers. C57BL/6 mice were infected intranasally with ECTV and ECTVΔ154. Spleen, liver, lung, and kidney tissue were harvested at days 2, 3, 4, and 7 post-
infection and viral titers were determined on BSC-40 cells (n¼5). (E and F) Survival of mice. C57BL/6 mice were infected intranasally with ECTV and ECTVΔ154 and survival
was monitored up to 21 days post-infection.
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multi-step growth curve is often indicative of a defect in spread,
these conclusions are often drawn with additional data that
supports a defect in spread following deletion of the gene in
question. Since we have not determined the exact mechanism of
B4, we draw our conclusions with caution. We also recognize that
using a high MOI in many of our experiments may have obscured
the effects of deleting B4R. Future experiments will include
assessing gene synthesis, virion formation, and actin tails at a
low MOI, to ensure that a high MOI did not partially overcome
defects that we observed during a single growth cycle. Moving
forward, additional studies will be necessary to conﬁrm and
elucidate the mechanism of B4; however, this study suggests that
B4 might contribute to virion release and spread. Overall, our
study provides new insights into the poxvirus lifecycle and raises
the question of whether we have identiﬁed all the ORFs involved
in virion release and spread.
Materials and methods
Cell lines and virus strains
BSC-1 and BSC-40 cells were obtained from the American Type
Culture Collection (ATCC) and Buffalo green monkey kidney
(BGMK) from Diagnostic Hybrids. U20S cells stably expressing a
cytoplasmic mutant of the Cre recombinase (U20S-Cre) were
kindly provided by Dr. J. Bell, University of Ottawa. Cells were
grown at 37 1C in 5% CO2 in Dulbecco's Modiﬁed Eagle medium
(DMEM) supplemented with 10% newborn calf serum (NCS)
(Invitrogen), 50 U/mL of penicillin (Invitrogen), 50 U/mL of strep-
tomycin (Invitrogen), and 200 μM of L-glutamine (Invitrogen).
Vaccinia virus strain Copenhagen (VACV) was provided by
Dr. G. McFadden (University of Florida, USA). Vaccinia virus strain
811 (VACV811), which is missing 55 ORFs from the variable regions
of the VACV genome, was provided by E. Paoletti (Perkus et al.,
1991). Ectromelia virus strain Moscow (ECTV) was provided by
Dr. M. Buller (St. Louis University, USA). All viruses were propa-
gated in BGMK cells as previously described (Stuart et al., 1991).
Plasmid constructs
pDGloxP was described previously (Rintoul et al., 2011).
pDGloxP contains a yellow ﬂuorescent protein (YFP)/guanine
phosphoribosyltransferase (gpt) fusion open reading frame under
the control of a poxvirus early/late promoter. The promoter and
open reading frame are ﬂanked by loxP sites. pDGloxP-ΔB4R was
constructed by PCR ampliﬁcation of 400-nucleotide sequences
located directly upstream and downstream of B4R in the VACV
genome. The upstream region of homology was ampliﬁed using
the following primers: forward 50-(SpeI)–ACT AGT CAA GGT
ATA TAA ACC TGG-30 and reverse 50-(HindIII)–AAG CTT ATA TAA
TTT ATA TTC TGT AAC ATG TTA-30. The downstream region
of homology was ampliﬁed using the following primers: forward
50-(NotI)–GC GGC CGC ACA CTA TTA AAA TAT AAA-30 and reverse
50-(BglII)–AGA TCT TAG TGT CAT GGT GGA AAT-30. The 400 base
pair amplicons were cloned into pGEM-T using the SpeI and HindIII
restriction sites for the upstream region, and NotI and BglII for the
downstream region. The sequences were subcloned into the
pDGloxP vector to create pDGloxP-DB4R. pDGloxP-Δ154 was
constructed by ampliﬁcation of the 200-nucleotide sequences
located directly upstream and downstream of EVM154 in the
ECTV genome, using Taq polymerase (Invitrogen Corporation).
The upstream region of homology was ampliﬁed using the
following primers: forward 50-(XhoI)–CTC GAG ATC ATA TAG ACA
ATA ACT-30 and reverse 50-(HindIII)–AAG CTT GAC ATA TAA TTT
ATA TTC TGT-30. The downstream region of homology was
ampliﬁed using the following primers: forward 50-(BamHI)–GGA
TCC AAT CTA AGT AGG ATA AAA-30 and reverse 50-(NotI)–GC GGC
CGC AAA CGA TGT TTC GGT AGA-30. The 400 base pair sequences
were cloned into pGEM-T using the XhoI and HindIII restriction
sites for the upstream region, and BamHI and NotI for the down-
stream region. Next, the sequences were digested and subcloned
into the pDGloxP vector to create pDGloxP-Δ154.
Generation of recombinant viruses
Recombinant viruses were generated as described previously
(Rintoul et al., 2011). Recombinant viruses containing the YFP/gpt
marker, VACVΔB4R and VACV811ΔB4R, were generated by infect-
ing BGMK cells with VACV or VACV811 at a MOI of 0.01 and
transfecting with 10 μg of linearized pDGloxP-DB4R using Lipo-
fectamine 2000 (Invitrogen Corporation) (Gammon et al., 2010;
Rintoul et al., 2011) for one hour post-infection. Recombinant virus
ECTVΔ154 was generated by infecting BGMK cells with ECTV at a
MOI of 0.01 and transfecting with 10 μg of linearized pDGloxP-
Δ154 using Lipofectamine 2000 one hour post-infection. Recom-
binant viruses were selected using media containing 25 μg/mL
mycophenolic acid (MPA) (Sigma-Aldrich), 250 μg/mL xanthine
(Sigma-Aldrich), and 15 μg/μL hypoxanthine (Sigma-Aldrich).
YFPþ recombinants were screened visually using an inverted
ﬂuorescent microscope (Leica). Marker-free ECTVΔ154, lacking
drug resistance and ﬂuorescent markers, was generated in order
to infect mice. The YFP/gpt-containing virus was passaged through
U20S-Cre cells and plaques were screened using the absence of
YFP as an indicator that excision by the Cre recombinase had
occurred. To generate the revertant viruses, VACVΔB4R-rev and
VACV811ΔB4R-rev, primers to the 50 end of the upstream ﬂanking
region and the 30 end of the downstream ﬂanking region of the
gene were used to generate a PCR product using VACV or VACV811
as a template. BGMK cells were infected with VACVΔB4R and
VACV811ΔB4R at a MOI of 0.01 followed by transfection with
the PCR product. Absence of YFP indicated that recombination
had occurred, and the gene was re-inserted. PCR analysis of
viral genomes veriﬁed deletion and reinsertion of the B4R and
EVM154 ORFs.
Plaque assays
Viruses were serially diluted and titred on BGMK cells (1106).
Plaques were allowed to form over 2–5 days and cells were stained
with crystal violet. Fifteen randomly isolated plaques were photo-
graphed for each sample using an Axioscope 2 plus microscope
(Zeiss) at a magniﬁcation of 2.5 and measured in ImageJ v1.44i
(National Institutes of Health). The edge of the plaque (deﬁned by
the edge of cells that had piled) was traced using the shape tool in
ImageJ. The experiment was performed in triplicate. Plaque sizes
were compared using GraphPad Prism version 5 and statistical
signiﬁcance was determined using a one-way ANOVA with a
Tukey post-test (GraphPad Software, La Jolla California USA,
www.graphpad.com).
Growth curves
Single-step growth curves were performed by infecting six-
well dishes of BGMK cells (1106) with the indicated viruses at a
MOI of 10. One hour post-infection, cells were washed with warm
PBS and 2 mL of supplemented DMEM were added back to each
well. Media and cells were harvested at the indicated times post-
infection and released from cells by freeze thaw. Titers were
determined in duplicate on BGMK cells. The experiment was
performed in triplicate. Alternatively, multi-step growth curves
were performed by infecting BGMK cells at a MOI of 0.01 and
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harvesting samples at the indicated times post-infection. For
multi-step growth curves, no wash step was performed 1 h post-
infection. Titers were determined in duplicate on BGMK cells, and
the experiment was performed in triplicate.
Immunoblot analysis
Six-well dishes of BGMK cells (1106) were mock-infected or
infected with the indicated virus at a MOI of 10. Whole cell lysates
were collected at the indicated times post-infection in 150 μL of
sodium dodecyl sulfate (SDS)-containing sample buffer and
samples were separated by SDS-polyacrylamide gel electrophor-
esis (SDS-PAGE). Proteins resolved by SDS-PAGE were transferred
to a nitrocellulose membrane (Fisher Scientiﬁc) for 2 h at 420 mA
using a semi-dry transfer apparatus (TYLER Research Instruments)
and transfer buffer containing 192 mM glycine, 25 mM Tris, and
20% v/v methanol. Membranes were blocked for 3 h at room
temperature in 5% w/v skimmed milk in Tris-buffered saline with
Tween 20 (TBS-T), containing 200 mM Tris (pH 7.5), 15 mM NaCl,
and 0.1% v/v Tween-20 (Fisher Scientiﬁc). Samples were immuno-
blotted overnight with mouse anti-E3L (Weaver et al., 2007),
mouse anti-B5R (Izmailyan et al., 2006), rabbit anti-A34R (Irwin
and Evans, 2012), rabbit anti-I5L (Wilton et al., 2008), and mouse
anti-b-tubulin (ECM Biosciences) antibodies, followed by the
appropriate secondary antibody, either Peroxidase-conjugated
AfﬁniPure goat anti-rabbit (Jackson Laboratories) or Peroxidase-
conjugated AfﬁniPure goat anti-mouse (Jackson Laboratories).
Proteins were visualized using enhanced chemiluminescence
(ECL) (GE Healthcare) and Amersham Hyerﬁlm ECL (GE Health-
care). To quantify relative levels of protein, membranes were
instead blocked for one hour at room temperature with commer-
cial blocking buffer (Licor), and immunoblotted overnight with
mouse anti-B5R (Izmailyan et al., 2006), rabbit anti-A34R (Irwin
and Evans, 2012), rabbit anti-I5L (Wilton et al., 2008), or mouse
anti-I3L (Lin et al., 2008) followed by incubation with IR-680- or
IR-800-conjugated secondary antibodies (Licor). Protein levels
were visualized using an Odyssey Imager (Licor) and relative
levels were determined compared to I3.
Electron microscopy
BGMK cells (1105) grown on 13 mm poly-L-lysine-coated
coverslips (Thermanox) were infected at a MOI of 10 with VACV,
VACVΔB4R, VACV811, or VACV811ΔB4R. Twenty-four hours post-
infection, cells were ﬁxed with 4% glutaraldehyde/2% paraformal-
dehyde, 0.2 M sucrose and 4 mM CaCl2 in 0.16 M sodium cacody-
late buffer (pH 7.4) at 37 1C for one hour. Following ﬁxation,
coverslips were washed with 0.05 M sodium cacodylate buffer to
remove aldehyde from the ﬁxative, and the lipids were then ﬁxed
with 1% ice-cold osmium tetoxide (OsO4) in 0.05 M sodium
cacodylate buffer. Following lipid ﬁxation, coverslips were again
washed with 0.05 M sodium cacodylate buffer. To increase con-
trast, cells were blocked in en bloc stain with 1% uranyl acetate in
0.1 M sodium acetate buffer (pH 5.2) for 15 min. Coverslips were
washed with 0.1 M sodium acetate buffer followed by Milli-Q
ﬁltered water and than dehydrated with increasing ethanol con-
centrations (30%, 50%, 70%, 80%, 90%, 95% and 100%) in propylene
oxide. Cells were inﬁltrated with a mixture of embed 812 and
araldite 502 resins and embedded on gelatin capsules before being
thermally polymerized at 60 1C for 48 h. Ultra-thin sections with a
thickness of 60 nm were generated using a Leica UC7 ultramicro-
tome (Leica Microsystems, Inc.) and contrasted with 2% uranyl
acetate and Reinolds' lead citrate. Sections were imaged using a
Hitachi H-7650 transmission electron microscope (Hitachi-High
Technologies) at 80 kV and a 16 mega pixel TEM camera (XR111,
Advanced Microscopy Techniques, MA, USA).
Media release experiments
Six-well dishes of BGMK cells (1106) were infected at a MOI
of 10 with VACV, VACVΔB4R, VACV811, or VACV811ΔB4R. One
hour post-infection, cells were washed twice with PBS to remove
any unbound virus, and fresh media was added. Twenty-four
hours post-infection, media was removed and centrifuged at
1000g for 10 min. The supernatant was then transferred to a
new tube and titered to determine the number of virions released
into the media. The cell layer was harvested with PBS, freeze-
thawed three times, and then titered to determine the number of
virions associated with the cell. The amount of released virus, as a
percent of total virus (releasedþcell-associated) was then calcu-
lated. The experiment was performed in triplicate, and standard
error of the mean (SEM) was determined.
Immunoﬂuorescence microscopy
Immunoﬂuorescence microscopy was performed as previously
described (Irwin and Evans, 2012). BSC-40 cells (2105) were
seeded on coverslips and mock-infected or infected at a MOI of
10 with VACV, VACVΔB4R, VACV811, or VACV811ΔB4R. Twenty
hours post-infection, cells were ﬁxed with 4% w/v paraformalde-
hyde (Sigma-Aldrich) in PBS for 30 min on ice. Cells were permea-
bilized with 100 mM glycine in PBS-T, washed three times, and
blocked for 30 min with 3% BSA in TBS-T. Cells were incubated for
one hour with mouse anti-B5, washed with PBS-T, and incubated
with Cy5-conjugated secondary antibody (Molecular Probes).
Following a one hour incubation with secondary antibody, cells
were counterstained with rhodamine phalloidin (0.3 U/mL) and
5 ng/mL DAPI for 20 min, and washed six times with PBS-T.
Coverslips were mounted using Mowiol mounting medium con-
taining 0.1 mg/mL Mowiol, 0.1 M PBS (pH 7.4), 25% glycerol, and
2.4% triethylenediamine (DABCO). Cells were visualized using the
60 oil immersion objective of a personal Delta-vision micro-
scope. Number of actin tails per cell were quantiﬁed by counting
150 infected cells over three independent trials.
Six to 11 weeks old female C57BL/6 mice were obtained from
the National Cancer Institute (Frederick, MD). Five female mice
with similar body mass were infected intranasally with 10-fold
escalating doses of ECTV or ECTVΔ154. Body weights were
monitored daily. Mice were sacriﬁced at 2, 3, 4, and 7 days post-
infection, and tissue from the spleen, liver, lungs, and kidney were
harvested. Tissue was homogenized using a tissue homogenizer
(Next Advance), followed by dilution in PBS (10% w/v). Viral
titers were determined on BSC-1 cells. To prevent avoidable
suffering, mice demonstrating a drop in body weight to 70% of
their original mass, or signs of severe morbidity, were euthanized.
These experiments were performed in accordance with mouse
ethics outlined by the Canadian Council on Animal Care and the
University of Alberta.
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